Zylox-Tonbridge Medical Technology Co., Ltd. disclosed that it repurchased 49,500 H Shares on-market on 4 May 2026, paying a volume-weighted average price of HK$22.81 per share. The transaction totalled HK$1.13 million, with prices ranging from HK$22.32 to HK$23.00.

Post-transaction, issued shares outstanding (excluding treasury shares) fell by 0.0148 % to 327.51 million, while treasury shares increased to 8.85 million. The company’s total issued share count remains unchanged at 336.35 million.

The buyback was executed under the repurchase mandate approved on 30 May 2025, which authorises the company to repurchase up to 31.96 million shares. Including this latest transaction, Zylox-Tonbridge has repurchased 6.03 million shares to date, equivalent to 1.84 % of the issued shares on the mandate’s reference date. A 30-day moratorium on new share issues or treasury‐share sales is now in place until 3 June 2026, as stipulated by Hong Kong listing rules.

All requisite regulatory confirmations were provided, affirming that the repurchase complied with the Hong Kong Stock Exchange’s Main Board Rules and relevant legal requirements.